NTRB
Nutriband Inc.4.4900
-0.3500-7.23%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
54.58MP/E (TTM)
-Basic EPS (TTM)
-3.05Dividend Yield
0%Recent Filings
10-Q
8-K
FDA greenlights Nutriband's fentanyl patch plans
Nutriband Inc. completed a key FDA meeting on September 18, 2025, securing feedback on CMC plans for its AVERSA FENTANYL abuse-deterrent patch, confirming the 505(b)(2) NDA pathway and guidance on manufacturing validation and abuse studies. The company now integrates this input toward an IND filing for a Human Abuse Potential study, partnering with Kindeva to address fentanyl patch risks like misuse and accidental exposure. FDA's support highlights the unmet need. No abuse-deterrent fentanyl patch exists yet.
10-Q
Q2 FY2026 results
Nutriband's Q2 FY2026 revenue climbed 40.6% y/y to $622K from Pocono Pharmaceuticals, driving gross profit up 54.5% to $157K with margins expanding to 25.2% on better sales mix, while 4P Therapeutics contributed nothing amid a focus shift. Yet operating loss widened to $2.0M from $1.4M y/y, fueled by SG&A jumping 117% to $1.6M on compensation costs, though R&D eased 27% to $563K from Kindeva efficiencies. Net loss hit $2.0M or $2.12/share after a $21.8M preferred dividend, versus $1.7M or $0.15/share last year; EPS aligns with 11.2M diluted shares, no anti-dilution flagged. Cash swelled to $7.0M on $5.3M warrant exercises, funding $2.7M ops burn, with $176K debt at low rates and $5M related-party line available. No M&A, but Kindeva deal eyes $3.6M more for NDA. Ongoing Gunnar lawsuit risks distractions.
8-K
Warrant exercises boost cash
Nutriband Inc. disclosed exercises of outstanding options and warrants from February 1 through July 31, 2025, injecting $5,349,709 in total proceeds. Stock options for 20,055 shares fetched $44,206, public warrants (NTRBW) for 47,076 shares brought $302,699, while private warrants for 778,041 shares yielded $5,002,804. This cash influx bolsters liquidity. No risks detailed.
8-K
Preferred stock dividend issued
Nutriband Inc. issued 3,008,643 shares of Series A Convertible Preferred Stock as a dividend to common shareholders on record July 25, 2025, at one preferred share per four common shares held. This followed board-approved amendments to its Articles of Incorporation on July 9, 2025, authorizing up to 10 million such shares, non-voting and convertible to common stock only after FDA approval of its AVERSA™ transdermal products. Shares remain restricted until SEC registration and Nasdaq listing. Investors await regulatory greenlight.
ASBP
Aspire Biopharma Holdings, Inc.
0.10-0.00
ATXI
Avenue Therapeutics, Inc.
0.67+0.02
BSEM
BioStem Technologies, Inc.
3.84-0.11
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENSC
Ensysce Biosciences, Inc.
1.18-0.07
ENVB
Enveric Biosciences, Inc.
5.24-0.12
LPCN
Lipocine Inc.
3.15+0.00
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NTRR
Neutra Corp.
0.00+0.00